| SCHEDULE OF CONTRACT LIABILITIES |
Contract
liabilities as of September 30, 2022 and 2021 are as follows:
SCHEDULE
OF CONTRACT LIABILITIES
| | |
September
30, 2022 | | |
September
30, 2021 | |
| Contract liabilities
beginning balance | |
$ | 135,150 | | |
$ | — | |
| Billings and cash receipts
on uncompleted contracts | |
| 325,048 | | |
| 281,012 | |
| Less:
revenues recognized during the period | |
| (303,648 | ) | |
| (145,862 | ) |
| Total
contract liabilities | |
$ | 156,550 | | |
$ | 135,150 | |
|
| SCHEDULE OF ANTI-DILUTIVE SHARES OUTSTANDING |
SCHEDULE
OF ANTI-DILUTIVE SHARES OUTSTANDING
| | |
2022 | | |
2021 | |
| | |
September
30, | |
| | |
2022 | | |
2021 | |
| Stock warrants | |
| 1,888,813,005 | | |
| 984,470,116 | |
| Stock options | |
| 1,901,410,519 | | |
| - | |
| Series C-1 preferred stock | |
| 156,626,175 | | |
| 445,301,289 | |
| Series C-2 preferred stock | |
| 453,067,129 | | |
| 733,542,619 | |
| Series E preferred stock | |
| 638,977,636 | | |
| 638,977,636 | |
| Series F preferred stock | |
| 319,488,818 | | |
| 319,488,818 | |
| Convertible
notes | |
| 1,813,880,837 | | |
| 319,488,711 | |
| Total antidilutive securities
excluded from computation of earnings | |
| 7,172,264,119 | | |
| 3,441,269,189 | |
|